Mitochondrial fusion promoter M1 是线粒体动态调节剂。Mitochondrial fusion promoter M1 保持线粒体功能并促进细胞呼吸。Mitochondrial fusion promoter M1 减轻了心肌缺血/再灌注大鼠的心脏损伤和大脑损伤。
| 生物活性 | Mitochondrial fusion promoter M1 is a mitochondrial dynamic modulator. Mitochondrial fusion promoter M1 preserves the mitochondrial function and promotes cellular respiration. Mitochondrial fusion promoter M1 alleviates cardiac and brain damage in rats with cardiac ischemia/reperfusion injury[1][2][3]. |
体外研究
(In Vitro) | Mitochondrial fusion promoter M1 (5-25 μM; 24 h) promotes mitochondrial elongation in both Mitofusin-1 and Mitofusin -2 knock-out fibroblasts[2].
Mitochondrial fusion promoter M1 (20 μM; 12 h) decreases mito ROS to 1.0±0.44 fold, enhances mitochondrial membrane potential from 0.29±0.05 fold to 0.5±0.07 fold and restores mitochondrial architecture in BRIN-BD11 pancreatic beta cells[3].
Mitochondrial fusion promoter M1 (20 μM; 12 h) prevents the impairment of oxygen consumption rate in pancreatic beta cells due to cholesterol exposure[3].
Mitochondrial fusion promoter M1 (20 μM; 12 h) prevents the impairment of non-mitochondrial respiration and extracellular acidification rate (ECAR) in cholesterol enriched pancreatic beta cells[3].
Mitochondrial fusion promoter M1 (20 μM; 12 h) restores Glucose Stimulated Insulin Secretion (GSIS) in cholesterol treated pancreatic beta cells[3].
|
体内研究
(In Vivo) | Mitochondrial fusion promoter M1 (2 mg/kg; i.v.) significantly protects rats with cardiac I/R injury against brain damage[1].
| Animal Model: | Male Wistar rats (250-300g) receiving cardiac ischemia/reperfusion (I/R)[1] | | Dosage: | 2 mg/kg | | Administration: | I.v. 15 minutes before cardiac I/R injury | | Result: | Increased brain mitochondrial fusion.
Increased blood-brain barrier (BBB) tight junction protein, and reduced macrophage infiltration in the brain.
Reduced brain mitochondrial dysfunction and apoptosis, but it did not reduce mitochondrial oxidative stress.
Reduced the expression of Alzheimer’s disease (AD)-related proteins. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 50 mg/mL(137.34 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.7469 mL | 13.7344 mL | 27.4688 mL | | 5 mM | 0.5494 mL | 2.7469 mL | 5.4938 mL | | 10 mM | 0.2747 mL | 1.3734 mL | 2.7469 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (5.71 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.71 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 2. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 0.5 mg/mL (1.37 mM); Clear solution; Need ultrasonic
此方案可获得 0.5 mg/mL (1.37 mM) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 0.5 mg/mL (1.37 mM); Suspended solution; Need ultrasonic
此方案可获得 0.5 mg/mL (1.37 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com